Figure 2.

Kaplan‐Meier survival curves showing the overall survival of ALK‐positive NSCLC patients treated with immune checkpoint inhibitors. ALK, anaplastic lymphoma kinase; NSCLC, non‐small‐cell lung cancer; PD‐1, programmed death 1; PD‐L1, programmed death ligand 1.